A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.

scientific article published on 15 December 2014

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/JVH.12372
P698PubMed publication ID25496007
P5875ResearchGate publication ID269637062

P2093author name stringS Cohen
J Zhao
J Hanson
E Hughes
V Rustgi
E Cooney
H Tatum
R Ghalib
C Martorell
M DeMicco
E Lawitz
P J Thuluvath
J Zamparo
M Treitel
N Ravendhran
P2860cites workGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceQ28255243
Telaprevir for previously untreated chronic hepatitis C virus infectionQ29619800
Sofosbuvir for previously untreated chronic hepatitis C infectionQ29620137
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionQ33797808
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymeraseQ33798031
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infectionQ34607097
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvirQ36276803
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymeraseQ40368140
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionQ42258200
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.Q42287899
Factors that predict response of patients with hepatitis C virus infection to boceprevirQ42980646
P433issue8
P921main subjectplaceboQ269829
ribavirinQ421862
P304page(s)658-664
P577publication date2014-12-15
P1433published inJournal of Viral HepatitisQ15749962
P1476titleA randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
P478volume22